Arcus Biosciences, Inc. — Director's Dealing 2020

Dec 18, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2020-12-17

Reporting Person: Tang Carolyn C. (General Counsel)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7348	Direct
Common Stock	33000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.574	2027-08-30	Common Stock (34090)		Direct
Stock Option (Right to Buy)	$5.3856	2028-01-03	Common Stock (31564)		Direct
Stock Option (Right to Buy)	$14.47	2028-09-03	Common Stock (30000)		Direct
Stock Option (Right to Buy)	$9.47	2029-01-27	Common Stock (40000)		Direct
Stock Option (Right to Buy)	$11.86	2029-03-20	Common Stock (25000)		Direct
Stock Option (Right to Buy)	$9.12	2029-09-11	Common Stock (139346)		Direct
Stock Option (Right to Buy)	$11.68	2030-02-08	Common Stock (100000)		Direct

Footnotes

F1: Represents the grant of restricted stock units that vest in four equal annual installments on each of June 15, 2021, June 15, 2022, June 15, 2023 and June 15, 2024, subject to the Reporting Person's continued service to the Company.

F2: The option is exercisable in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued service to the Company.